Inhibikase Therapeutics (IKT) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Inhibikase Therapeutics (IKT) has outperformed Vanda Pharmaceuticals (VNDA) over the past year, gaining 18.7% versus a loss of 16.1%. Over five years, VNDA leads with a -75.2% price change compared with -83.0% for IKT. Vanda Pharmaceuticals is the larger company by market cap ($276.3 million vs $274.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IKT | VNDA |
|---|---|---|
| Share price | $1.97 | $4.57 |
| Market cap | $274.89M | $276.31M |
| 1-day change | +3.14% | +0.88% |
| YTD return | -3.90% | -48.19% |
| 1-year return | +18.67% | -16.15% |
| 5-year return | -82.99% | -75.18% |
| Forward P/E | — | 22.85 |
| EPS (TTM) | $-0.43 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $9.94 |
| 52-week low | $1.33 | $4.27 |
| Distance from 52-week high | -24.52% | -54.02% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +204.57% | +157.11% |
| Average volume | 653.92K | 980.33K |
| Shares outstanding | 139.54M | 60.46M |
| Employees | 35 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IKT has outperformed VNDA by 34.8 percentage points over the past year.
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
IKT vs VNDA FAQ
Which is bigger, Inhibikase Therapeutics or Vanda Pharmaceuticals?
Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $276.31M compared with $274.89M for Inhibikase Therapeutics (IKT).
Which stock has performed better over the past year, IKT or VNDA?
IKT returned +18.67% over the past 12 months, compared with -16.15% for VNDA (price return, excluding dividends). Past performance does not predict future results.
Are Inhibikase Therapeutics and Vanda Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Inhibikase Therapeutics and Biotechnology: Pharmaceutical Preparations for Vanda Pharmaceuticals.